Detecting Metastatic Patterns of Oligometastatic Breast Cancer: A Comparative Analysis of

18F-FDG PET/CT OMD breast cancer oligometastatic breast cancer

Journal

Journal of nuclear medicine : official publication, Society of Nuclear Medicine
ISSN: 1535-5667
Titre abrégé: J Nucl Med
Pays: United States
ID NLM: 0217410

Informations de publication

Date de publication:
18 Apr 2024
Historique:
received: 23 10 2023
revised: 05 03 2024
medline: 19 4 2024
pubmed: 19 4 2024
entrez: 18 4 2024
Statut: aheadofprint

Résumé

Metastasis-directed therapy has the potential to improve progression-free and overall survival in oligometastatic disease (OMD). For breast cancer, however, randomized trials have failed so far to confirm this finding. Because the concept of metastasis-directed therapy in OMD is highly dependent on the accuracy of the imaging modality, we aimed to assess the impact of

Identifiants

DOI: 10.2967/jnumed.123.266925 PMID: 38637138
pubmed: 38637138
pii: jnumed.123.266925
doi: 10.2967/jnumed.123.266925
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© 2024 by the Society of Nuclear Medicine and Molecular Imaging.

Auteurs

Rebecca Moser (R)

Department of Radiation Oncology, Klinikum Rechts der Isar, TUM School of Medicine and Health, Technical University Munich, Munich, Germany.

Sophie Pfeiffer (S)

Department of Radiation Oncology, Klinikum Rechts der Isar, TUM School of Medicine and Health, Technical University Munich, Munich, Germany.

Lisena Cala (L)

Department of Nuclear Medicine, Klinikum Rechts der Isar, TUM School of Medicine and Health, Technical University Munich, Munich, Germany.

Evelyn Klein (E)

Department of Obstetrics and Gynecology, Klinikum Rechts der Isar, TUM School of Medicine and Health, Technical University Munich, Munich.

Marion Kiechle (M)

Department of Obstetrics and Gynecology, Klinikum Rechts der Isar, TUM School of Medicine and Health, Technical University Munich, Munich.

Sophie T Behzadi (ST)

Department of Radiation Oncology, Klinikum Rechts der Isar, TUM School of Medicine and Health, Technical University Munich, Munich, Germany.

Eva Fallenberg (E)

Department of Obstetrics and Gynecology, Klinikum Rechts der Isar, TUM School of Medicine and Health, Technical University Munich, Munich.

Stephanie E Combs (SE)

Department of Radiation Oncology, Klinikum Rechts der Isar, TUM School of Medicine and Health, Technical University Munich, Munich, Germany.
Department of Radiation Sciences, Germany Institute of Innovative Radiotherapy, Helmholtz Zentrum München, Oberschleißheim, Germany; and.
German Consortium for Translational Cancer Research, Munich, Germany.

Wolfgang Weber (W)

Department of Nuclear Medicine, Klinikum Rechts der Isar, TUM School of Medicine and Health, Technical University Munich, Munich, Germany.

Kai J Borm (KJ)

Department of Radiation Oncology, Klinikum Rechts der Isar, TUM School of Medicine and Health, Technical University Munich, Munich, Germany; kai.borm@mri.tum.de.

Classifications MeSH